Adults seeking the strongest available weight-loss outcome in a brand-name SKU Adults with obesity and moderate-to-severe OSA (cross-listed indication) Adults with pre-diabetes and obesity who want T2D progression prevention Clients who plateaued on a semaglutide SKU and want a tirzepatide trial Clients comfortable with weekly subcutaneous injection In SURMOUNT-5, a 72-week head-to-head trial sponsored by Eli Lilly, adults on Zepbound (tirzepatide) achieved 20.2% mean body weight loss, compared with 13.7% for adults on Wegovy (semaglutide)
Its important to remember that GLP-1s are not one-size-fits-all
Symptoms include persistent fatigue and low energy, brain fog and poor concentration, low mood, anxiety or depression, memory problems, tingling or numbness in hands and feet, poor sleep quality, weakened immune function and hair thinning and loss
Its about finding ways to feel stronger, manage chronic conditions, and regain a sense of control over your own body and life
Compounding under the shortage pathway specifically ended when each shortage was resolved
,aspect=ignore)
